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Abstract
Following the widespread use of genome-wide association studies (GWAS), focus is turning towards identification of causal
variants rather than simply genetic markers of diseases and traits. As a step towards a high-throughput method to identify
genome-wide, non-coding, functional regulatory variants, we describe the technique of allele-specific FAIRE, utilising large-
scale genotyping technology (FAIRE-gen) to determine allelic effects on chromatin accessibility and regulatory potential.
FAIRE-gen was explored using lymphoblastoid cells and the 50,000 SNP Illumina CVD BeadChip. The technique identified an
allele-specific regulatory polymorphism within NR1H3 (coding for LXR-a), rs7120118, coinciding with a previously GWAS-
identified SNP for HDL-C levels. This finding was confirmed using FAIRE-gen with the 200,000 SNP Illumina Metabochip and
verified with the established method of TaqMan allelic discrimination. Examination of this SNP in two prospective Caucasian
cohorts comprising 15,000 individuals confirmed the association with HDL-C levels (combined beta = 0.016; p= 0.0006), and
analysis of gene expression identified an allelic association with LXR-a expression in heart tissue. Using increasingly
comprehensive genotyping chips and distinct tissues for examination, FAIRE-gen has the potential to aid the identification
of many causal SNPs associated with disease from GWAS.
Citation: Smith AJP, Howard P, Shah S, Eriksson P, Stender S, et al. (2012) Use of Allele-Specific FAIRE to Determine Functional Regulatory Polymorphism Using
Large-Scale Genotyping Arrays. PLoS Genet 8(8): e1002908. doi:10.1371/journal.pgen.1002908
Editor: Gregory S. Barsh, Stanford University School of Medicine, United States of America
Received February 23, 2012; Accepted July 2, 2012; Published August 16, 2012
Copyright:  2012 Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the British Heart Foundation (BHF) (PG/07/133/24260, RG/08/014, SP/07/007/23671) and a Senior Fellowship to AD
Hingorani (FS/2005/125). SE Humphries is a BHF Chair. M Kumari’s work on this manuscript was partially supported by the National Heart, Lung, and Blood
Institute (NHLBI: HL36310). The WH-II study has been supported by grants from the Medical Research Council; British Heart Foundation; Health and Safety
Executive; Department of Health; National Institute on Aging (AG13196), NIH; Agency for Health Care Policy Research (HS06516); and the John D. and Catherine T.
MacArthur Foundation Research Networks on Successful Midlife Development and Socio-Economic Status and Health. The ASAP study was supported by the
Swedish Research Council (12660), the European Commission (FAD, Health F2 2008 200647), and a donation by Fredrik Lundberg. A Tybjærg-Hansen was
supported by the Danish Medical Research Council (grant no. 10-083788), the Research Fund at Rigshospitalet, Copenhagen University Hospital, Chief Physician
Johan Boserup and Lise Boserup’s Fund, Ingeborg and Leo Dannin’s Grant, Henry Hansen’s and Wife’s grant, and a grant from the Order of Odd Fellows. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Andrew.J.P.Smith@ucl.ac.uk
Introduction
The proliferation of genome-wide association studies (GWAS) has
achieved considerable advances concerning the identification of novel
genetic loci associated with phenotypic traits and diseases, and also
confirmedmany established genetic associations. Following GWAS, the
next objective in genetics will be identification of the causal variants
marked by current GWAS, and determination of the molecular
mechanisms altered by these genetic variants. This step will be another
majormilestone towards realisation of the fundamental goal for GWAS,
in developing novel drug targets based on this new genetic information.
Only a small percentage of GWAS hits are themselves non-
synonymous coding SNPs, with their expected causality by
changing protein structure and function. The majority of GWAS
hits occur within intronic and intergenic regions of the genome
and are likely to exert their effects at the level of gene regulation
[1]. Due to the complex nature of gene regulation [2], with
regulatory elements commonly occurring up to 100 kb from a
transcription start site (TSS), identifying the causal SNP from
potentially hundreds of other SNPs that are simply in near or
complete linkage disequilibrium (LD) with one identified from
GWAS, is a challenging undertaking.
The ENCODE project has significantly increased our under-
standing of the location of regulatory elements throughout the
genome [3]. Using techniques such as chromatin immunoprecip-
itation followed by sequencing (ChIP-seq), we now know the
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genomic binding sites for some of the key transcription factors (TF)
involved in gene regulation in a number of experimental tissues.
This technique relies on the existence of a ChIP-grade antibody to
recognise each DNA-bound transcription factor, and is the major
limitation towards the complete characterisation of all human TF
binding sites [4]. A more widespread use of ChIP-seq has been the
annotation of the genome for histone methylation signatures, such
as H3K4me1 and H3K4me3, strong markers of enhancers and
promoters [5]. Other sequencing techniques have been used to
map the genome for open chromatin, including DNase I
hypersensitivity (DNase-seq) [6] and formaldehyde-assisted isola-
tion of regulatory elements (FAIRE-seq) [7]. These regions of open
chromatin correlate extremely highly with both histone methyl-
ation signatures and TF ChIP-seq, but in contrast to ChIP-seq, are
able to identify regulatory regions without prior knowledge of a
specific transcription factor involved.
If a non-coding SNP associated with gene regulation were to be
functional, it would be expected to alter not only transcription
factor binding, but also histone methylation signatures and
chromatin accessibility. We have applied this hypothesis to
identify the functionality of SNPs on a larger scale than has
previously been possible, using gene chip technology. In this paper
we describe a method for allele-specific FAIRE using gene chip
technology, we term FAIRE-gen, to identify possible candidate
functional SNPs in loci related to cardiovascular disease.
Results
Use of FAIRE-gen to Determine Allele-Specific
Enrichment of Regulatory Regions
To examine the potential to use gene chips to assess allele-
specific FAIRE, three lymphoblastoid cell lines were examined
following IL-1b stimulation to induce cell proliferation [8].
Subsequent to cell fixing, chromatin extraction and sonication,
the fragmented chromatin was divided into two groups for each
cell line: a control DNA and a FAIRE-enriched DNA sample. For
the control DNA, the crosslinks were reversed and the DNA
purified; for the FAIRE-enriched DNA, the chromatin underwent
three rounds of phenol:chloroform extraction to enrich the sample
for open chromatin, followed by reversal of crosslinks and DNA
purification. Both samples were standardised to 50 ng/ml and
genotyping performed using the Illumina CVD BeadChip, a
custom-designed chip containing 49,094 SNPs from gene loci
selected to play a potential role in cardiovascular disease (Figure 1).
Genotyping call frequencies for sonicated control DNA were
comparable to non-fragmented DNA (97.2% vs 98.1%); whereas
those for FAIRE-enriched DNA were significantly lower (56.7%).
Using an existing lymphoblastoid FAIRE-seq dataset, the level of
enrichment at the location of the CVD BeadChip SNPs was
compared with the FAIRE-gen samples. The logR ratio output
from the Illumina GenomeStudio was used to indicate the level of
allelic amplification and therefore FAIRE-gen enrichment, com-
pared to the respective control samples. A strong association of
mean FAIRE-gen-enriched allelic intensity with FAIRE-seq peak
intensity was observed (p= 2.34610282, Figure 2). The reduced
amplification of alleles outside of open chromatin results in
decreased genotype clustering and a lower call-rate in the FAIRE-
enriched samples.
Following FAIRE, an allelic effect on open chromatin would
enrich one allele over the other in a heterozygous individual. To
examine whether this small dataset was large enough to identify an
allele-specific effect on open chromatin, each sonicated control
sample and its respective FAIRE-enriched sample was examined
using the B allele frequency (BAF), which measures the proportion
of the genotype from an individual attributed to the B allele (often
the minor allele). To ensure a consistent allelic effect was found,
only SNPs that were heterozygous in all three cell lines were
examined. This reduced the number of SNPs under analysis to
3,129.
These 3,129 heterozygous SNPs were examined for allelic
enrichment, where the control BAF and FAIRE-enriched BAF
were compared for each cell line. One SNP showed a statistical
significant difference with all three cell lines after applying the
Bonferroni correction: rs7120118 (Figure 3), where the C allele
was enriched in open chromatin. The fact that only a single
association was identified was not unexpected for such a
genotyping chip, where the SNP coverage per gene is low and
concentrated within coding regions, where the majority of genes
covered do not overlap with eQTLs or GWAS studies, and
considering the very small number of cell lines examined. Despite
only one SNP reaching the Bonferroni cut-off, there was overall
enrichment in the study for p-values,0.05 (Figure S1), highlight-
ing the potential for a greater number of significant results with a
larger sample.
The SNP that did show statistical significance is located within
intron 6 of NR1H3, coding for LXR-a. Examining genomic
annotations for this SNP on the UCSC Genome Browser, it can be
seen that not only is this SNP located in a region of open
chromatin by DNase I-seq [9,10], FAIRE-seq [7,11] and with
enhancer-specific histone methylation signatures [5,12] (Figure 4),
it has also been identified as a GWAS SNP for HDL-C levels [13].
Replication of rs7120118 FAIRE-gen Using 200K SNP
Illumina Metabochip
To confirm the effects seen using the Illumina CVD BeadChip
on rs7120118 with allele-specific FAIRE, the study was replicated
using the Illumina Metabochip, a consortia custom-designed
genotyping chip, containing 196,726 SNPs to primarily examine
associations identified by GWAS for cardiometabolic traits and
diseases, those in strong LD, and also a number of rare variants.
The Metabochip contains rs7120118, and seven out of the eight
further SNPs identified as in complete LD with rs7120118 from
the CEU panel in the 1000 Genome Project.
A total of 20 lymphoblastoid cells were examined, including
new FAIRE preparations for the original three cell lines. 6
Author Summary
The identification of genetic variants associated with
complex diseases has rapidly grown through lowering
costs of genome sequencing and the use of large-scale
genotyping chips based on this sequencing data. There
have not been corresponding advances in the identifica-
tion of causal genetic variants compared to variants simply
associated with diseases or traits. Most of these causal
variants are thought to be located not within regions
coding for proteins, but within genomic regions that
regulate the level of protein. We have combined the use of
large-scale gene chips with functional analysis, to deter-
mine regions of the genome that confer a greater
potential for controlling gene regulation dependent on
the genotype of that individual. Combining this data with
population data and gene expression data, we identify a
potential causal variant that alters regulation of LXR-a, a
key mediator in lipid metabolism, and show that this
variant is associated with HDL-C levels. This methodology
provides a model for future analyses to identify further
causal variants for disease.
Allele-Specific FAIRE Using Genotyping Arrays
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additional cell lines were heterozygous for rs7120118, excluding
the three previously examined. Comparing BAF between sonicat-
ed controls and FAIRE DNA for these 6 cell lines, the C allele was
again enriched in the FAIRE sample (control BAF= 0.44, FAIRE-
enriched BAF=0.67, p = 0.0036).
The seven SNPs in complete LD with rs7120118 were
examined by the same analysis from the Metabochip using all 9
heterozygous cell lines. Unlike the original Illumina CVD
BeadChip assay, Metabochip FAIRE-gen was performed on both
unstimulated and IL-1b-stimulated lymphoblastoid cell lines,
allowing a direct comparison of IL-1b stimulation on allele-
specific open chromatin. The results for all analyses are shown in
Table 1. The rs7120118 C allele was enriched with and without
IL-1b stimulation by 15.5% (p= 0.008) and 4.4% (p= 0.022),
respectively. No other SNPs from the seven in complete LD with
rs7120118 in the IL-1b-stimulated cell lines showed allelic
enrichment. From the stimulated cell lines there was a trend
towards BAF enrichment from the adjacent SNP rs2279239
(11.3%, p= 0.01, Figure 5), contained within the same region of
open chromatin, but this did not reach statistical significance when
Figure 1. Principle of High-Throughput Analysis of Open Chromatin Using FAIRE-gen. In this example, two potentially functional GWAS
SNPs which are in complete LD are illustrated: SNP 1, a T.C, where the C allele occurs in a region of open chromatin, relative to allele T; and SNP 2, a
G.A, where both SNPs occur within open chromatin. Following formaldehyde-fixing and sonication, the T allele from SNP 1 remains tightly bound
within the nucleosome. Upon phenol:chloroform extraction, this DNA-bound nucleosome transfers to the solvent layer, whilst the C allele within
open chromatin remains in the aqueous layer and is purified. Upon genotyping with a gene chip, the C allele is enriched compared to the T allele. For
SNP 2, the polymorphism does not affect chromatin structure; both alleles are equally enriched following FAIRE. This would suggest that SNP 1 was
the more likely causal SNP for the GWAS association, conferring a greater allele-specific regulatory potential.
doi:10.1371/journal.pgen.1002908.g001
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correcting for multiple comparisons. Examining the unstimulated
cell lines, two further SNPs showed modest allelic imbalance
following FAIRE: rs2167079 (exon 1 of ACP2), with a 10.3%
reduction in BAF (p= 0.003) and rs326222 (intron 8 of DDB2)
with a 4.9% reduction in BAF (p = 0.003).
Use of TaqMan Allelic Discrimination to Confirm Allele-
Specific Genotyping
To confirm the allele-specific enrichment from the C allele of
rs7120118, genotyping of the 20 sonicated control and FAIRE
samples was carried out using the TaqMan platform for allelic
discrimination. Allelic ratios were determined by extrapolation
from a standard curve of the vic/fam ratio from samples of known
genotype. The allelic ratios do not differ significantly from the
Metabochip data, confirming the ability for gene chips to provide
a suitable high-throughput method for FAIRE-gen (Figure 6).
Confirmation of rs7120118 as a Marker for HDL-C Plasma
Levels
The SNP showing the greatest and most consistent allelic effect
for open chromatin, and confirmed in two subsequent genotyping
platforms, rs7120118, has been identified using GWAS as being
associated with plasma HDL-C levels [13]. The SNP was
associated with a beta coefficient of 0.04 (0.0073 SE,
p= 6.761028), but this finding has not been replicated in further
GWAS, and not reported in a recent meta-analysis of lipid traits
comprising .100,000 individuals [14]. To confirm the original
association, we examined this SNP in a prospective UK cohort of
4724 individuals from the Whitehall II study. Baseline character-
istics of the study are shown in Table 2. This data replicated the
reported association with an HDL-C raising effect from the C
allele (beta = 0.016, p = 0.0059). No other SNPs in strong LD with
this SNP (r2.0.5) showed significantly greater effect sizes (Table 3).
An additional cohort, the Copenhagen City Heart Study (CCHS;
n=10,322, baseline characteristics shown in Table 2) was
genotyped for rs7120118, and this also showed a similar effect
size (beta = 0.015, p = 0.041, Table 4). Combining the two datasets
in a meta-analysis using a fixed-effects model did not alter the
effect size (beta = 0.016) although increased the significance
(p=0.0006). As there is an association between gender and
HDL-C levels in the general population, we also carried out
stratification for gender. This showed a similar direction of effect
in both studies, showing that the effect seen with rs7120118
functionality is unlikely to be gender-specific. This correlates with
Figure 2. Correlation of FAIRE LogR Ratio with FAIRE-seq
Peaks. The graph shows the correlation of FAIRE-enriched SNP
intensity using Illumina CVD BeadChip with FAIRE-seq peak intensity
from the GM12878 lymphoblast cell line. The (mean log R ratio from
three FAIRE-enriched DNAs) – (mean log R ratio from their respective
control DNAs) were compared with known FAIRE-seq intensities (0 = no
FAIRE-seq enrichment; 1–200= lowest level of FAIRE-seq enrichment;
800–1000=highest FAIRE-seq enrichment). There is a strong correlation
between SNP intensity and FAIRE-seq peak intensity (p = 2.34610282).
doi:10.1371/journal.pgen.1002908.g002
Figure 3. Allele-Specific Open Chromatin Signals from Heterozygous Lymphoblast Cell Lines. Manhattan plot showing allele-specific
signals of open chromatin using the Human CVD beadchip. The BAF of chromosome 11 SNP, rs7120118 (C allele), is significantly enriched following
FAIRE-gen, in an examination of 3,129 SNP heterozygous SNPs in 3 lymphoblast cell lines. No other SNP showed significant allele-specific effects for
open chromatin.
doi:10.1371/journal.pgen.1002908.g003
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the functional in vivo findings, where the rs7120118 C allele is
associated with open chromatin in cells from both male and female
origin (data not shown).
Effects of rs7120118 on Gene Expression
To determine if the association of rs7120118 with both HDL-C
levels and open chromatin was also associated with an interme-
diate phenotype of NR1H3 gene expression, this SNP was
examined in five tissue samples from 316 patients undergoing
aortic valve surgery. A significant allele-specific effect was observed
in heart tissue (p = 0.0127) (Figure 7), with a trend towards
significance in aortic adventitia (P = 0.154). In both cases the C
allele of rs7120118 was associated with an upregulation of NR1H3
expression.
Discussion
We have examined the possibility of using high-throughput gene
chips to examine the allele-specific nature of open chromatin using
FAIRE (illustrated in Figure 1). The study identified a functional
SNP, rs7120118, where the minor C allele is enriched in open
chromatin and associated with increased HDL-C. Although the
level of significance for HDL-C levels was adequate for a SNP with
an a priori hypothesis, this would be much lower than required for
genome-wide significance, highlighting the importance of com-
bining functional studies with GWAS to identify candidate SNPs
for disease or trait associations, particularly those with lower
effect sizes, rare SNPs or small cohorts. Indeed, examining a
recent meta-analysis of lipid traits in .100,000 individuals,
rs7120118 did show a strong association with HDL-C levels
(p = 1.297610214, Figure 8) although this was not reported as
significant in the study [14], perhaps due to the strong LD in the
region, with the association signals covering .29 genes. We have
shown that the minor allele is associated with increased NR1H3
gene expression in heart tissue and aortic adventitia, adding to a
previous genome-wide study revealing a significant association
with rs7120118 and gene expression of NR1H3 and ACP2 in
lymphoblast cells [15]. From this data it can be postulated that
rs7120118 directly affects a long-range regulatory element
(.15 kb from NR1H3 TSS) in a non-tissue-specific manner,
altering gene expression and HDL-C levels.
The principle of allele-specific FAIRE was previously applied by
Gaulton et al to examine the functionality of a single type II
diabetes (T2D) GWAS SNP in TCF7L2 [16]. The authors used
Figure 4. UCSC Genome Browser Annotation of rs7120118 Locus on Human Mar. 2009 (NCBI37/hg19) Assembly. The annotated
region surrounding rs7120118 (SNP highlighted in red box) reveals the location of a putative enhancer, with typical features including H3K4me3
signatures, DNase I hypersensitivity and FAIRE-seq enrichment in a number of tissues. The SNP lies between two regions of transcription factor
binding sites, including a c-Fos/c-Jun (AP-1 heterodimers), p300 (a transcriptional co-activator), YY1, SRF, GATA-2 complex, and a USF-1 binding site.
doi:10.1371/journal.pgen.1002908.g004
Figure 5. Replication of Allele-Specific Effect of rs7120118 from 9 Heterozygous IL-1b Stimulated Lymphoblast Cell Lines Using
Illumina Metabochip. The boxplots indicate the effect size of allele-specific differences in open chromatin. Included are the 7 SNPs in high LD. The
B allele (rs7120118 C) is enriched in open chromatin, as is the adjacent SNP, rs2279239 with less statistical significance.
doi:10.1371/journal.pgen.1002908.g005
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FAIRE-seq to determine global tissue-specific regions of open
chromatin in pancreatic tissue, followed by TaqMan allelic
discrimination to ascertain the effect of a single putative functional
SNP on open chromatin. They found that the allele conferring
increased risk of T2D and higher gene expression was also
associated with enrichment for open chromatin. Although
successfully demonstrating the use of FAIRE to identify a causal
SNP from a GWAS, the use of TaqMan would not be applicable
for examining a large number of potentially functional SNPs.
FAIRE-gen, in contrast is only restricted by the number of SNPs
that can fit on a genotyping chip.
The action of IL-1b on chromatin structure, a cytokine known
to induce proliferation of EBV-transformed lymphoblasts [8], was
examined in this study to reveal further potential allele-specific
differences in open chromatin under different environmental
conditions. For rs7120118, an allele-specific effect was observed in
both unstimulated and IL-1b-stimulated cell lines, although the
effects were stronger in the IL-1b stimulated samples. The action
of IL-1b activates NF-kB, potentially altering expression of
transcription factors that bind to the regulatory region surround-
ing rs7120118. Indeed, a nearby cluster of transcription factor
binding sites determined by ChIP-seq includes a site for c-Jun
binding (Figure 4); the JUN promoter contains several NF-kB
binding sites (UCSC Genome Browser hg19/NCBI37) [3], which
may explain this enhanced effect. It could be hypothesised that the
C allele that favours open chromatin allows for preferential access
for known, or as yet uncharacterised, transcription factors, which
would act as an enhancer for NR1H3 gene expression, and
increased HDL-C levels.
In contrast, a potential allelic effect was observed with the
promoter SNP rs2167079 (in complete LD with rs7120118), only in
unstimulated cells. IL-1b is known to reduce expression of NR1H3
in HK-2 cells [17], and it could be postulated that IL-1bmay lead to
chromatin remodelling and a decrease in open chromatin at the
NR1H3 promoter in lymphoblasts, accounting for the lack of allelic
effect in the IL-1b-stimulated cells. Alternatively, the modest allele-
specific chromatin effects from the unstimulated cell lines could
simply represent false-positive findings.
Table 1. Examination of rs7120118 and SNPs in complete LD with this using Metabochip FAIRE-gen in 9 heterozygous
lymphoblastoid cell lines.
IL-1b stimulated
SNP rs7120118 rs2279239 rs59663860 rs35879051 rs2167079 rs901746 rs2013867 rs326222
control BAF 0.446 0.466 0.494 0.499 0.552 0.485 0.486 0.494
FAIRE BAF 0.601 0.579 0.457 0.491 0.498 0.512 0.505 0.535
difference 0.155 0.113 20.037 20.009 20.055 0.027 0.019 0.040
p 0.008 0.010 0.111 0.669 0.259 0.192 0.356 0.065
Unstimulated
SNP rs7120118 rs2279239 rs59663860 rs35879051 rs2167079 rs901746 rs2013867 rs326222
control BAF 0.469 0.490 0.521 0.498 0.539 0.499 0.503 0.506
FAIRE BAF 0.513 0.514 0.503 0.509 0.436 0.483 0.490 0.458
difference 0.044 0.024 20.018 0.011 20.103 20.016 20.013 20.049
p 0.022 0.176 0.100 0.447 0.003 0.405 0.569 0.003
doi:10.1371/journal.pgen.1002908.t001
Figure 6. Replication of the Allele-Specific Effect of rs7120118
from 9 Heterozygous Lymphoblast Cell Lines Using the Taq-
Man Platform. The effect of C allele-enrichment from the Illumina
Metabochip is confirmed using an alternative method of allele-
quantification from the TaqMan platform.
doi:10.1371/journal.pgen.1002908.g006
Table 2. Baseline characteristics of the Whitehall II study
(including all individuals examined on both CVD BeadChip
and Metabochip) and the Copenhagen City Heart Study
(CCHS).
Baseline characteristics WHII CCHS
Total participants, No. 5059 10322
Women (%) 1338 (26) 5754 (56)
Age, years 49 (44–54) 59 (45–69)
Body mass index (kg/m2) 25 (23–27) 25 (22–28)
Total cholesterol (mmol/L) 6.4 (5.7–7.2) 6.0 (5.1–6.9)
HDL cholesterol (mmol/L) 1.4 (1.1–1.7) 1.5 (1.2–1.8)
LDL cholesterol (mmol/L) 4.4 (3.7–5.0) 3.6 (2.9–4.4)
Triglycerides (mmol/L) 1.4 (0.8–1.7) 1.5 (1.1–2.2)
Values are number and (%) or median and (interquartile range).
doi:10.1371/journal.pgen.1002908.t002
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Haplotype structure may also affect local chromatin, particu-
larly where more than one SNP occurs in the same region of open
chromatin. We have examined the variation surrounding
rs7120118 using HapMap-derived genotypes for the lymphoblasts
used in the Metabochip study. No further SNPs at the locus
provided additional haplotypic information for the effects on open
chromatin, suggesting that rs7120118, rather than a haplotype, is
responsible for this observation.
To assess the reproducibility of the FAIRE-gen methodology,
the two Metabochip datasets were examined, considering the
second IL-1b-treated study as a replicate. Examining the SNPs
showing an allele-specific effect on open chromatin from the
untreated samples, following Bonferroni correction (p,5.26107;
n=127), 100% were replicated in the treated sample with
significance set at p,0.05, (91% replicated with Pc,3.9610
24;
n=116), indicating the sensitivity of the assay. The sensitivity and
specificity of the assay to identify true functional variants can only
be accurately determined by further functional analysis of each
putative SNP. The smallest detectable difference in allele-specific
open chromatin for the SNPs reaching genome-wide Bonferroni
cut-off in the Metabochip was 10% (rs75106522).
One limitation with FAIRE-gen, as opposed to FAIRE-seq is
the dependence of the gene chip to contain all relevant SNPs for
the trait under examination. For the recent custom-designed chips
which contain dense markers and aim to include all SNPs that tag
GWAS-identified markers for diseases and related traits, such as
the Illumina Metabochip and Immunochip, this is less of a
problem. Future genotyping chips containing all common SNPs
associated with diseases/traits could potentially resolve this
drawback. For determining the location of potential causal SNPs
from a number of SNPs acting as proxies, FAIRE-gen is only able
to identify single allele-specific SNPs if other proxies are not
located within the same region of open chromatin. This can be
illustrated for rs7120118, where a nearby SNP, rs2279239, is
located only 4.6 kb away, and close to the same region of open
chromatin (Figure S2). This SNP shows a similar trend for allelic-
specificity, although somewhat reduced due to the distance from
the putative causal SNP.
Since the assay includes data from SNPs that are not present in
open chromatin, there may also be a number of false-positive
associations from the methodology, where amplification from
background (non-open) chromatin may, in theory, preferentially
occur for one allele. For this reason, replication using FAIRE-gen
or FAIRE-seq in a separate study, and in vitromethodologies would
be desirable to confirm functionality.
In conclusion, FAIRE-gen shows promise as an economical,
high-throughput method to enable targeted unbiased detection of
allele-specific regulatory elements, which may help to refine
GWAS disease-association signals to identify disease-causing
variants.
Materials and Methods
Ethics Statement
The Whitehall II study was approved by the UCL Research
Ethics Committee, and participants gave informed consent to each
aspect of the study. The CCHS was approved by institutional
review boards and Danish ethical committees, and conducted
according to the Declaration of Helsinki. Written informed
consent was obtained from all participants.
Cell Lines and Culture
20 EBV-transformed lymphoblastoid cell lines, derived from the
Centre d’Etude du Polymorphism Humain (CEPH) panel (Coriell
Cell Repositories, identifiers listed in table S1), were cultured in
Table 3. Associations of SNPs in LD with rs7120118 and HDL-
C levels in 3,413 individuals from the WHII study.
snp
r2 with
rs7120118 BETA p
rs10838692 0.959 0.02107 0.002977
rs3816725 0.959 0.02076 0.003413
rs10838681 0.833 0.02038 0.006481
rs11039119 0.544 0.004251 0.5476
rs3758668 0.517 0.01596 0.08267
doi:10.1371/journal.pgen.1002908.t003
Table 4. Meta-analysis using fixed-effect model of associations of rs7120118 and HDL-C in CCHS and WHII, stratified by gender.
WHII CCHS Meta-Analysis
SNP
Risk
Allele Samples Beta (95% CI) P N Beta (95% CI) P N Beta (95% CI) P
rs7120118 C all 0.016
(0.0046–0.027)
0.0059 4724 0.015
(0.00063–0.029)
0.041 10322 0.016
(0.0066–0.024)
0.0006
rs7120118 C males 0.018
(0.0048–0.031)
0.0077 3481 0.088
(20.00997–0.0276)
0.358 4568 0.015
(0.0041–0.026)
0.0067
rs7120118 C females 0.0096
(20.012–0.031)
0.39 1243 0.023 (0.004–0.042) 0.018 5754 0.017
(0.0029–0.032)
0.019
doi:10.1371/journal.pgen.1002908.t004
Figure 7. Effect of rs7120118 on NR1H3 Gene Expression in
Tissue. A) Effect of rs7120118 genotype on NR1H3 gene expression in
heart samples (n = 127). The minor allele (C) is associated with increased
expression at p= 0.0127. B) Effect of rs7120118 genotype on NR1H3
gene expression in aortic adventitia samples (n = 133). There is a trend
towards increased expression of NR1H3 with the C allele (p=0.154).
doi:10.1371/journal.pgen.1002908.g007
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RPMI 1640 (PAA) with 2 mM L-glutamine and 15% fetal bovine
serum (PAA) at 37uC, 5% CO2. Cell viability was verified using
the ADAM-MC cell counter (Digital Bio), and minimum cell
viability for experiments was $99%. Stimulation of cells was
carried out by an overnight incubation in serum-free media, and
addition of 5 ng/ml IL-1b, two hours prior to cell fixing.
Chromatin Fixing, Isolation, and Sonication
16108 cells were cultured for each experiment and incubated
with 1/10 volume of fresh 11% formaldehyde for 20 min. 1/20
volume of 2.5 M glycine was added to quench formaldehyde. Cells
were washed 3 times in PBS and resuspended in 10 ml lysis buffer
1 (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA,
10% glycerol, 0.5% NP-40, 0.25% Triton-X-100, 16 protease
inhibitors) for 10 min. After centrifugation, the supernatant was
discarded and pellet resuspended in 10 ml lysis buffer 2 (10 mM
Tris-HCL, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 16 protease inhibitors) for 10 mins. The nuclei were
pelleted and resuspended in 3.5 ml lysis buffer 3 (10 mM Tris-
HCL, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA,
0.1% NA Deoxycholate, 0.5% N-lauroylsarcosine, 16 protease
inhibitors). Sonication was performed using the Bioruptor
sonicator (Wolflabs, York, UK) and optimized to produce
maximum enrichment of fragments 100–1000 bp, prior to
downstream analysis. 1/10 volume of 10% Triton X was added
to the sonicated sample, the sample centrifuged at 20,000 g and
the lysate stored on ice.
Formaldehyde-Assisted Isolation of Regulatory Elements
(FAIRE) and Genotyping
Following chromatin fixing, isolation and sonication, the
sheared lysate was subject to three rounds of phenol:chloroform
extraction, followed by a final chloroform extraction. The DNA
was ethanol precipitated and the pellet resuspended in TE buffer.
The DNA solution was treated with 0.2 mg/ml RNase A and
incubated at 37uC, and 0.2 mg/ml proteinase K at 55uC for two
hours. Samples were incubated at 65uC overnight to remove
crosslinks. The samples were subjected to a further phenol:chloro-
form extraction and ethanol precipitation and standardised to
50 ng/ml for Illumina genotyping chips. For each respective
control sample, 10% of the fixed and sonicated chromatin was
reverse-crosslinked at 65uC overnight, treated with 0.2 mg/ml
RNase A and incubated at 37uC for two hours and 0.2 mg/ml
proteinase K at 55uC for 2 hours. The samples underwent 3
rounds of phenol:chlororom extraction followed by ethanol
precipitation and standardisation to 50 ng/ml for Illumina
genotyping. Genotyping was carried out using the Illumina
CVD BeadChip and Illumina Metabochip. Genotype calls for
control samples were generated using Illumina GenomeStudio
software. Call rates for control and FAIRE samples are described
in the Results.
Whitehall II Study (WHII)
DNA was extracted from whole blood. Genotyping for 6,156
samples and laboratory analysis of has been described previously
Figure 8. Association of rs7120118 with HDL-C in More Than 100,000 Individuals. Association of rs7120118 with HDL-C levels was examined
using a published dataset from a study in more than 100,000 individuals [14] using LocusZoom [27] to plot the SNPs examined and imputed from 1000
Genomes Project dataset. A high level of LD is present within the locus, with at least 29 genes implicated with HDL. rs7120118 is indicated in purple
(p= 1.297610214), with the SNPs in strongest LD marked in red. Although not statistically the lead SNP at this region, with the additional effects of this
SNP on open chromatin, NR1H3 gene expression, and proximity to NR1H3, rs7120118 is represents a good functional candidate.
doi:10.1371/journal.pgen.1002908.g008
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[18]. 5529 samples were genotyped using the Illumina CVD
BeadChip [19] and 3,413 samples were genotyped using the
Illumina Metabochip. Genotype calls were generated using
Illumina GenomeStudio software. After filtering for duplicates,
cryptic relatedness, ambiguous gender, self-reported non-Cauca-
sians, outliers based on the genome-wide identity-by-state analysis
implemented in PLINK, sample call rate.80% and SNP call
rate.98%, 5059 CVD BeadChip and 3126 Metabochip geno-
typed samples were available for analysis.
Copenhagen City Heart Study (CCHS)
The CCHS [20,21] is a prospective study of the Danish general
population initiated in 1976–78 with follow-up examinations in
1981–84, 1991–94, and 2001–03. Individuals were randomly
selected to represent the Danish general population aged 20 to 80+
years. We included 10,322 participants who gave blood for DNA
analysis at the 1991–94 and/or 2001–03 examinations. The study
was approved by institutional review boards and Danish ethical
committees, and conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all
participants. Plasma levels of total cholesterol, LDL cholesterol,
HDL cholesterol, and triglycerides were measured using standard
hospital assays (Konelab, Helsinki, Finland, and Boehringer
Mannheim, Mannheim, Germany). LDL cholesterol was calcu-
lated using the Friedewald equation if the triglyceride level was less
than 4 mmol per liter (354 mg per deciliter) and was measured
directly for higher triglyceride levels. Follow-up studies of
rs7120118 in the samples from Copenhagen were performed
using an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems Inc, Foster City, California, USA) and a
TaqMan-based assay.
Expression Studies
Tissue biopsies (mammary artery, ascending thoracic aorta and
liver) were taken from patients undergoing aortic valve surgery as
part of the Advanced Study of Aortic Pathology (ASAP) study [22].
Aortic biopsies were divided into intimal-medial and adventitial
halves. Peri-aortic fat was removed from the adventitial specimens
where present. RNA from the tissue biopsies was hybridized to
Affymetrix ST 1.0 Exon arrays and obtained scans were RMA
normalized and log2 transformed. eQTL analysis was performed
with an imputed genotype from circulating blood DNA (Illumina
610w-Quad BeadArrays). The full methods for this study have been
described previously [22].
Statistical Analysis
Comparison of the GM12878 lymphoblast FAIRE-seq data
track was obtained from the UCSC Genome Browser (http://
hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC/wgEncode
ChromatinMap/wgEncodeUncFAIREseqZinbaGm12878.narrow
Peak.gz) and compared to (mean logR ratio of SNPs following FAIRE-
enrichment) - (mean log R ratio for the respective control SNPs). The
mean SNP log R ratios stratified by strength of FAIRE-seq signal were
compared by ANOVA. A paired two-sided t-test was used to compare
the control BAF with the respective FAIRE-enriched BAF. Visualisa-
tion of Manhattan plots and data management from the UCSC
Genome Browser was carried out using Galaxy software [23–25]. In
WHII, linear regression analysis of log-transformedHDL-Cwith SNPs
using an additive model was performed using PLINK 1.0.7. Analysis
was carried out in all individuals and stratified by gender. Regression
analysis was performed unadjusted for covariates as well as gender
(only in analysis of all individuals) and age added as covariates. Stata
software, version 10 (Stata Corp, College Station, Texas) was used for
all analyses in the CCHS. Trend tests were by Cuzick’s nonparametric
test for trend. Linear regression was used to determine per-allele b-
coefficients. For trend tests and linear regression analysis, rs7120118
TT, TC and CC genotypes were coded as 0, 1, and 2, respectively.
Statistical analysis of gene expression was carried out using R-2.13.0
and Bioconductor 2.8 [26]. Association between gene expression and
genotype was calculated using an additive linearmodel as implemented
in the lm-function in R.
Supporting Information
Figure S1 Histogram of FAIRE-gen p-values for 50K CVD
BeadChip. The use of FAIRE-gen on the CVD BeadChip was
carried out with a very small number of samples, resulting in only
one SNP showing chip-wide significance in relation to chromatin
structure. The enrichment of p-values,0.05, indicates the
potential for a greater level of functionality to be derived from
the genotyping chip with the use of increased sample numbers.
(TIF)
Figure S2 UCSC Genome Browser Chromatin Annotations for
Variants in Complete LD with rs7120118. The map shows the
location of 8 SNPs in complete LD with rs7120118. Lymphoblast
open chromatin and H3K4me1 marks derived from the UCSC
Genome Browser are annotated. The regions of distinct
enhancers are highlighted in red, illustrating the location of
SNPs in complete LD with rs7120118 are in separate regions of
open chromatin to this SNP. The association of rs7120118 with
open chromatin is unlikely to be marking effects on open
chromatin from other SNPs in LD, although the nearest SNP in
complete LD (rs2279239) shows a similar, albeit reduced, effect
from FAIRE.
(TIF)
Table S1 Lymphobast cell lines used for FAIRE-gen. The cell
lines used for the CVD BeadChip and the Metabochip study are
indicated.
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